TrialsgrambetaRCTs are beautiful

RECOVERY (Tocilizumab)

2021

Tocilizumab in COVID-19

In 4,116 hospitalised hypoxic patients with COVID-19 and inflammation, tocilizumab reduced 28-day mortality compared with usual care.

Result

Efficacy: 28-day all-cause mortalityRR 0.85

Below 1 favours tocilizumab, above 1 favours usual care.

Event rates
Absolute difference
4 points

The absolute difference is derived from the event rates.

Also reported: Combined with dexamethasone in most patients.

Original publication
Subtopic
IL-6 antagonists
Design
Adaptive platform RCT, UK
Relevance
Important: one of several pillars.
Source
RECOVERY Collaborative Group. Lancet. 2021;397(10285):1637-1645.doi 10.1016/S0140-6736(21)00676-0

Discussion & critique

Confirmed REMAP-CAP signal; add tocilizumab in rapidly worsening, CRP-high patients on steroids.

Discussed in podcasts